Assessment of the receptor status in primary breast cancer with synchronous loco regional metastases: prognostic and clinical role?

Author:

Gordeeva O. O.1,Zhukova L. G.2,Kolyadina I. V.1,Ganshina I. P.1

Affiliation:

1. N.N. Blokhin Russian Cancer Research Center.

2. A.S. Loginov Moscow Clinical Scientific Center.

Abstract

Background. Assessment of hormone receptor status plays a crucial role in treatment of patients with breast cancer. currently, clinicians are limited to determining the expression status of estrogen receptor (ER), progesterone receptor (pR) and HER2 only in primary breast cancer tissues, even in the presence of regional metastases.The purpose of the study was to review available data on heterogeneity of ER, pR and HER2/neu expressions in primary breast cancer and regional metastases.Material and methods. We analyzed publications available from pubmed, medline etc. using the keywords «discordance», «breast cancer», «locally advanced», «regional lymph nodes», «ER», «pR», and «HER2».Results. The clinical and prognostic role in assessing the heterogeneity of the receptor status of primary tumors and synchronous regional metastases, as well as the effect of detected discordance on treatment tactics was assessed.Conclusion. Data on the frequency of discordance in hormone receptor status between primary and metastatic breast cancer tumors and its effect on the further prognosis in breast cancer are still contradictory. However, the fact of the presence of such heterogeneity suggests that some patients with affected lymph nodes will have significant benefits from determining the status of steroid hormones and HER2 not only in the primary tumor, but also in the lymph nodes, since it will open up new opportunities for subsequent targeted therapy.

Publisher

Tomsk Cancer Research Institute

Subject

Cancer Research,Oncology

Reference21 articles.

1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). М., 2018. 250. [Kaprin A.D., Starinskii V.V., Petrova G.V. Malignant tumors in Russia in 2016 (Morbidity and mortality). Moscow, 2018. 250. (in Russian)].

2. Fallahpour S., Navaneelan T., De P., Borgo A. Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open. 2017 Sep 25; 5 (3): E734E739. doi: 10.9778/cmajo.20170030.

3. Жукова Л.Г., Чичиков Е.И., Гордеева О.О., Филоненко Д.А. Палбоциклиб – новые возможности терапии гормон-позитивного HER2-негативного рака молочной железы. Фарматека. 2017; 17 (350): 24–29. [Zhukova L.G., Chichikov E.I., Gordeeva O.O., Filonenko D.A. Palbociclib – new possibilities of therapy of hormon-positive HER2-negative breast cancer. Pharmateca. 2017; 17 (350): 24–29. (in Russian)].

4. Ганьшина И.П., Лубенникова Е.В., Жукова Л.Г.Двойная блокада HER2-рецептора – новое направление в лечении рака молочной железы с гиперэкспрессией HER2. Фарматека. 2014; 8 (281): 75–79. [Gan’shina I.P., Lubennikova E.V., Zhukova L.G. The double blockade of the HER2 receptor is a new trend in the treatment of breast cancer with overexpression of HER2. Pharmateca. 2014; 8 (281): 75–79. (in Russian)].

5. Колядина И.В., Поддубная И.В. Современные возможности терапии HER2-положительного рака молочной железы (по материалам клинических исследований). Современная онкология. 2014; 16 (4): 10–20. [Kolyadina I.V., Poddubnaya I.V. Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials). Journal of Modern Oncology. 2014; 16 (4): 10–20. (in Russian)].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3